S. 113 · 118th Congress · Commerce
Prescription Pricing for the People Act of 2023
- IntroducedJan 26, 2023 Done
- CommitteeReported Mar 1, 2023 Done
- Senate floorDied Jan 3, 2025 Stopped here
- House floorNot yet Not reached yet
- Chambers agreeNot yet Not reached yet
- PresidentNot yet Not reached yet
What it does
This bill requires the Federal Trade Commission (FTC) to report about anticompetitive practices and other trends within the pharmaceutical supply chain that may impact the cost of prescription drugs. The FTC also must provide recommendations to increase transparency in the supply chain and prevent anticompetitive practices.
Congressional Research Service · summary of “Reported to Senate” version · Mar 1, 2023
Who lobbies on it
28 organizations · 165 filings · Q1 2023–Q4 2024These 28 organizations’ PACs gave $233K to 11 of the 20 members sponsoring or cosponsoring S. 113 in the 2025–26 election cycle.
One square per quarter since introduction, oldest left. Filled = named it that quarter.
-
Pharmaceutical Research and Manufacturers of America
8 of 8 quarters
“…S. 113: Prescription Pricing for the People Act of 2023 - Provisions related to PBMs S. 127: Pharmacy Benefit Manager Transparency Act of 2023 - Provisions related to PBMs S. 148: Stop STALLING Act - Provisions related to citizen petitions S. 1067: Ensuring Timely Access to Generics Act of 2023 S. 1130: Health Care…”
$31.0M lobbying spend in 2024, all issuesQ4 2024 filing
-
American Medical Association
8 of 8 quarters
“…S. 113, Prescription Pricing for the People Act of 2023, all provisions H.R. 7153, Dr. Lorna Breen Health Care Provider Protection Reauthorization Act, all provisions S. 3679, Dr. Lorna Breen Health Care Provider Protection Reauthorization Act, all provisions H.R. 830, Help Ensure Lower Patient (HELP) Copays Act, all…”
$24.3M lobbying spend in 2024, all issuesQ4 2024 filing
-
America's Health Insurance Plans Inc (ahip)
8 of 8 quarters
“…S. 113 - Prescription Pricing for the People Act of 2023 - Sen. Grassley, Chuck - PBM transparency S. 127 - Pharmacy Benefit Manager Transparency Act of 2023 - Sen. Cantwell, Maria - PBM transparency S. 142 - Preserve Access to Affordable Generics and Biosimilars Act - Sen. Klobuchar, Amy - pharmacy and biosimilar…”
$11.8M lobbying spend in 2024, all issuesQ4 2024 filing
25 more organizations, every filingPROUpgrade
Organizations that named S. 113 in a quarterly lobbying report. Covers organizations with a PAC on file; reports from organizations without one aren’t loaded yet. Spend is the organization’s total across all issues: reports don’t split spending by bill. “Gave to” means the organization’s PAC gave to the member’s campaign in the 2025–26 cycle, net of refunds; it doesn’t mean the money was about this bill. Organizations may lobby for, against, or to change a bill; filings don’t say which. Source: Senate lobbying disclosures (LD-2) from lda.gov; PAC gifts from FEC filings; quotes are word for word from the “specific lobbying issues” field; where a filing lists many bills, the quote starts where it names this one.
Actions
5 actions · newest first- Mar 1, 2023Placed on Senate Legislative Calendar under General Orders. Calendar No. 19.
- Mar 1, 2023Committee on the Judiciary. Reported by Senator Durbin with an amendment in the nature of a substitute. Without written report.
- Feb 9, 2023Committee on the Judiciary. Ordered to be reported with an amendment in the nature of a substitute favorably.
- Jan 26, 2023Read twice and referred to the Committee on the Judiciary.
Show all 5 actionsShow fewer
- Jan 26, 2023Introduced in Senate